FindTrial
Sign In

A CLINICAL TRIAL TO SEE THE EFFECT OF MAGNESIUM SULFATE DRUG IN OXYGEN DEPRIVATED NEWBORN

To study role of magnesium sulfate as a neuroprotective agent for perinata asphyxia in term neonates

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/08/006107
Enrollment
50
Registered
2015-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- neonates with perinatal asphyxia

Interventions

Intervention1: magnesium sulfate-drug: The treatment group received magnesium sulfate infusion at 250 mg/kg/dose in 20 ml of 5% dextrose solution in 1 hour OD for 3 days Control Intervention1: normal

Sponsors

MAHARANI LAXMI BAI MEDICAL COLLEGE JHANSI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: gestational age > 37 weeks , age < 6 hours, severe perinatal asphyxia

Exclusion criteria

Exclusion criteria: patients with severe intrauterine growth retardation, any condition unrelated to asphyxia, age > 6 hours at admission, maternal disorder, chromosomal anomalies or congenital malformation

Design outcomes

Primary

MeasureTime frame
neuroprotectiveTimepoint: 1 year—

Secondary

MeasureTime frame
not hypotensive at given doseTimepoint: 1 year—

Countries

India

Contacts

Public Contactvijay singh

maharani laxmi bai medical college, jhansi, uttar pradesh

drsethijhs@rediffmail.com7309934373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026